Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that the Crohn's disease drug market will experience dynamic growth of 73% by 2013. According to the new Pharmacor study entitled Crohn's Disease, the growth will be a direct result of the launch of novel biologic agents into the market.

"Several novel biologic agents in late-stage clinical development are expected to launch for the treatment of Crohn's disease in the next ten years," said Melissa G. Stolper, analyst at Decision Resources. "The launch of these emerging agents will expand the number of treatment options for patients with severe, refractory disease, and physicians will therefore be able to prescribe second- or third-line biologics for patients who fail to respond to a first-line biologic. The expanding percentage of patients who will be treated with biologics and the premium pricing of these new biologics will help drive composite 2013 sales for these emerging therapies to $843 milllion, a figure representing almost 50% of the overall Crohn's disease market in that year."

About Crohn's Disease

Crohn's disease is a chronic, relapsing/remitting inflammatory disease that predominantly affects the small and large intestines, including the rectum. In 2003, the diagnosed prevalent population in the seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) totaled more than 550,000.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Pressure Builds to Rein in Overprescribing of Antibiotics for the Treatment of Acute Exacerbations Of Chronic Bronchitis

View Now